TNSN07375A1 - Acides nucleiques de liaison a la ghreline - Google Patents

Acides nucleiques de liaison a la ghreline

Info

Publication number
TNSN07375A1
TNSN07375A1 TNP2007000375A TNSN07375A TNSN07375A1 TN SN07375 A1 TNSN07375 A1 TN SN07375A1 TN P2007000375 A TNP2007000375 A TN P2007000375A TN SN07375 A TNSN07375 A TN SN07375A TN SN07375 A1 TNSN07375 A1 TN SN07375A1
Authority
TN
Tunisia
Prior art keywords
segment
box
nucleic acids
ghrelin binding
double
Prior art date
Application number
TNP2007000375A
Other languages
English (en)
Inventor
Florian Jarosch
Dirk Eulberg
Christian Maasch
Steffen Helmling
Sven Klussmann
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of TNSN07375A1 publication Critical patent/TNSN07375A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

la présente invention concerne un acide nucléique, de préférence de liaison à la ghréline, cet acide nucléique comprenant un premier segment appel‚ Boite A et un second segment appel‚ Boite B, le premier segment Boite A comprenant environ 25 nucléotides consécutifs et le second segment Boite B comprenant environ six à huit nucléotides consécutifs, un segment 3 terminal de nucléotides du premier segment Boite A s'hybridant avec le second segment Boite B, ce qui provoque par hybridation la formation d'une première structure bicaténaire cette première structure bicaténaire comprenant ainsi un bombement.
TNP2007000375A 2005-04-08 2007-10-05 Acides nucleiques de liaison a la ghreline TNSN07375A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05007795 2005-04-08
PCT/EP2006/003276 WO2006108599A2 (fr) 2005-04-08 2006-04-10 Acides nucleiques se liant a la ghreline

Publications (1)

Publication Number Publication Date
TNSN07375A1 true TNSN07375A1 (fr) 2009-03-17

Family

ID=37087373

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000375A TNSN07375A1 (fr) 2005-04-08 2007-10-05 Acides nucleiques de liaison a la ghreline

Country Status (24)

Country Link
US (2) US8101734B2 (fr)
EP (1) EP1866412A2 (fr)
JP (2) JP5308813B2 (fr)
KR (1) KR20080009072A (fr)
CN (1) CN101189337B (fr)
AP (1) AP2007004189A0 (fr)
AR (1) AR052741A1 (fr)
AU (1) AU2006233647A1 (fr)
BR (1) BRPI0608180A2 (fr)
CA (1) CA2605377A1 (fr)
CR (1) CR9423A (fr)
DO (1) DOP2006000085A (fr)
EA (1) EA200701901A1 (fr)
GB (1) GB2439673A (fr)
GT (1) GT200600137A (fr)
IL (1) IL186085A0 (fr)
MA (1) MA29384B1 (fr)
MX (1) MX2007012419A (fr)
NL (2) NL1031538C2 (fr)
PE (1) PE20061358A1 (fr)
TN (1) TNSN07375A1 (fr)
TW (1) TW200718781A (fr)
UY (1) UY29460A1 (fr)
WO (1) WO2006108599A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4644599B2 (ja) * 2002-08-01 2011-03-02 ノクソン・フアルマ・アクチエンゲゼルシヤフト グレリン結合核酸
BRPI0415872A (pt) * 2003-11-10 2007-01-09 Noxxon Pharma Ag ácidos nucleìcos ligando especificamente à grelina bioativa
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
US9296810B2 (en) 2008-05-02 2016-03-29 Novartis Ag Fibronectin-based binding molecules and uses thereof
US8796216B2 (en) * 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
WO2011051327A2 (fr) 2009-10-30 2011-05-05 Novartis Ag Petites protéines à chaîne unique de type anticorps
WO2011051466A1 (fr) 2009-11-02 2011-05-05 Novartis Ag Molécules de liaison anti-idiotypiques à base de fibronectine et leurs utilisations
WO2011092233A1 (fr) 2010-01-29 2011-08-04 Novartis Ag Conjugaison de levures pour produire des combinaisons de liants à base de fibronectine à haute affinité
PT2726511T (pt) 2011-07-01 2019-10-14 Ngm Biopharmaceuticals Inc Composições, usos e métodos para o tratamento de distúrbios e doenças metabólicas
NZ630484A (en) 2012-11-28 2017-04-28 Ngm Biopharmaceuticals Inc Compositions and methods for treatment of metabolic disorders and diseases
CA2895517C (fr) 2012-12-27 2022-10-11 Ngm Biopharmaceuticals, Inc. Procedes de modulation de l'homeostasie de l'acide biliaire et traitement de troubles et de maladies de l'acide biliaire
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１０を疾病及び疾患の治療に用いる方法
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
WO2015077717A1 (fr) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (fr) 2013-12-20 2015-06-25 The Board Institute Inc. Polythérapie comprenant un vaccin à base de néoantigènes
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2015187295A2 (fr) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Méthodes permettant de faire baisser le cholestérol sérique
EP3206713A4 (fr) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Compositions d'interleukine-15 et leurs utilisations
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10517929B2 (en) 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
WO2016100977A1 (fr) 2014-12-19 2016-06-23 The Broad Institute Inc. Procédés pour le profilage du répertoire de récepteurs de cellules t
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016126615A1 (fr) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
KR20180010229A (ko) 2015-05-20 2018-01-30 더 브로드 인스티튜트, 인코퍼레이티드 공유 신생항원
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
MX2018002298A (es) 2015-08-25 2018-07-06 Armo Biosciences Inc Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
WO2017184590A1 (fr) 2016-04-18 2017-10-26 The Broad Institute Inc. Prédiction améliorée d'épitope hla
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3580561B1 (fr) 2017-02-12 2023-11-01 BioNTech US Inc. Méthodes et compositions reposant sur le hla et leurs utilisations
CN111315398A (zh) 2017-11-10 2020-06-19 阿尔莫生物科技股份有限公司 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
JP7097465B2 (ja) 2018-06-19 2022-07-07 アルモ・バイオサイエンシーズ・インコーポレイテッド キメラ抗原受容体細胞療法と併用するｉｌ－１０剤の組成およびその使用方法
WO2020072700A1 (fr) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Lignées d'allèles uniques d'alh
WO2020131586A2 (fr) 2018-12-17 2020-06-25 The Broad Institute, Inc. Méthodes d'identification de néo-antigènes
KR20240091046A (ko) 2018-12-21 2024-06-21 바이오엔테크 유에스 인크. Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
WO2020250923A1 (fr) * 2019-06-11 2020-12-17 味の素株式会社 Peptide et son utilisation
WO2020252039A1 (fr) 2019-06-12 2020-12-17 Biontech Us Inc. Compositions de néoantigènes et utilisations associées
EP4259206A2 (fr) 2020-12-14 2023-10-18 BioNTech US Inc. Antigènes spécifiques de tissu pour une immunothérapie anticancéreuse
WO2024077256A1 (fr) 2022-10-07 2024-04-11 The General Hospital Corporation Procédés et compositions pour la découverte à haut débit de protéines de liaison ciblant un peptide-cmh

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
ES2110444T3 (es) 1990-06-11 1998-02-16 Nexstar Pharmaceuticals Inc Ligandos de acidos nucleicos.
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
JPH11505527A (ja) 1995-05-03 1999-05-21 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 鏡像異性体リガンドの同定
DE19808591C2 (de) 1998-02-28 2000-02-03 Univ Leipzig Standardisierter durchflußzytometrischer Vollblutassay
US20030211967A1 (en) 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
WO2001087335A2 (fr) 2000-05-17 2001-11-22 Eli Lilly And Company Procede d'inhibition selective de la ghreline
WO2001092292A2 (fr) 2000-05-30 2001-12-06 Merck & Co., Inc. Analogues de la ghreline
ATE469164T1 (de) * 2001-10-26 2010-06-15 Noxxon Pharma Ag Modifizierte l-nukleinsäure
JP4644599B2 (ja) 2002-08-01 2011-03-02 ノクソン・フアルマ・アクチエンゲゼルシヤフト グレリン結合核酸
BRPI0415872A (pt) 2003-11-10 2007-01-09 Noxxon Pharma Ag ácidos nucleìcos ligando especificamente à grelina bioativa
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin

Also Published As

Publication number Publication date
NL1033520C2 (nl) 2010-01-21
UY29460A1 (es) 2006-11-30
AU2006233647A1 (en) 2006-10-19
US20060258607A1 (en) 2006-11-16
NL1031538A1 (nl) 2006-10-10
US8101734B2 (en) 2012-01-24
JP2013176372A (ja) 2013-09-09
CN101189337A (zh) 2008-05-28
GB2439673A (en) 2008-01-02
WO2006108599A2 (fr) 2006-10-19
JP2008534024A (ja) 2008-08-28
US20120115937A1 (en) 2012-05-10
AU2006233647A2 (en) 2008-04-17
AR052741A1 (es) 2007-03-28
MX2007012419A (es) 2007-12-05
WO2006108599A3 (fr) 2007-02-15
NL1031538C2 (nl) 2007-03-20
CA2605377A1 (fr) 2006-10-19
GT200600137A (es) 2006-11-22
DOP2006000085A (es) 2006-11-15
CN101189337B (zh) 2013-11-06
BRPI0608180A2 (pt) 2009-11-17
AP2007004189A0 (en) 2007-10-31
PE20061358A1 (es) 2007-01-13
GB0719489D0 (en) 2007-11-21
CR9423A (es) 2007-12-17
EP1866412A2 (fr) 2007-12-19
TW200718781A (en) 2007-05-16
MA29384B1 (fr) 2008-04-01
EA200701901A1 (ru) 2008-04-28
NL1033520A1 (nl) 2007-08-06
JP5308813B2 (ja) 2013-10-09
IL186085A0 (en) 2008-01-20
KR20080009072A (ko) 2008-01-24

Similar Documents

Publication Publication Date Title
TNSN07375A1 (fr) Acides nucleiques de liaison a la ghreline
MA28976B1 (fr) Multimeres d'oligonucleotides immunostimulateurs
ATE490260T1 (de) Mit lipidmembran attachments verwandte oligonukleotide
EP2039699A3 (fr) Procédés d'extraction pour purifier le sucralose
ATE513911T1 (de) Verfahren und zusammensetzungen für rna- interferenz
MA27725A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
TNSN07233A1 (fr) Macrolides
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
WO2002038806A3 (fr) Identification de polymorphismes d'acide nucleique
BRPI0307702B8 (pt) formulações de solução contendo anticorpo
BRPI0410713A (pt) liga ai-cu-mg-ag-mn para aplicações estruturais que exigem alta resistência e alta ductilidade
ATE443136T1 (de) Methode für dna synthese
EP2402451A3 (fr) Méthode de stabilisation d'un ADN inséré dans un vecteur de vaccinia recombinant
MA29274B1 (fr) Constructions d'acide nucleique
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
WO2001048183A3 (fr) Inhibition d'arn a double brin
RU2001112580A (ru) Сплав на основе титана
ATE541944T1 (de) Polynukleotidprimer
MX2009000654A (es) Medios para inhibir la expresion de la cinasa de proteina 3.
WO2006102970A3 (fr) Petit arn interferant modifie
BR9811580A (pt) Composições parentéricas de alatrofloxacina
WO2002103014A3 (fr) Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires
MA27746A1 (fr) Vaccins
UA84020C2 (ru) Ингибитор проникновения вируса вил
MX2008013416A (es) Medios para inhibir la expresion de cd31.